A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled "Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 ...

2024年12月底，美国国家综合癌症网络（NCCN）发布了2025.V1版非小细胞肺癌（NSCLC）临床诊疗指南（以下简称指南）。 此次指南的发布对NSCLC的临床分期 ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

近年来，EGFR 突变 Ⅲ 期不可切除非小细胞肺癌（NSCLC）的治疗已成为临床探索的热点。LAURA 研究是首个探索靶向治疗用于 EGFR 突变 Ⅲ 期不可切除 ...

Here we present a case of a patient with stage IV CD-74-ROS1 fusion NSCLC discovered initially with RNA next generation sequencing (NGS) who acquired ...

The prevalence of EGFR mutation rate positivity in NSCLC is high in Asia, and this is the case in Malaysia as well. This presentation will provide Malaysia’s approach in implementation of NGS in 1st ...

This test can help your team determine if and how ... This helps to determine a person’s treatment plan and prognosis. The ...

The global cancer diagnostics market size was valued at USD 106.32 billion in 2024 and is projected to reach from USD 112.60 ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Collaboration focuses on launching an AI-powered biomarker prediction panel targeting actionable biomarkers to revolutionize lung cancer diagnostics and enable commercialization of a diagnostic panel.